Loading...
Loading...
VOR| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 2.1M |
| Gross Profit | -2.1M |
| Operating Expense | 35.3M |
| Operating I/L | -35.3M |
| Other Income/Expense | 2.1M |
| Interest Income | 2.1M |
| Pretax | -33.2M |
| Income Tax Expense | 1.4M |
| Net Income/Loss | -33.2M |
Vor Biopharma, Inc. is a clinical-stage company specializing in engineered hematopoietic stem cell (eHSC) therapies for cancer patients. Their lead product candidate, VOR33, is in phase 1/2 for treating acute myeloid leukemia (AML) and other hematological malignancies. VOR33 eHSCs lack CD33, a protein expressed by AML blood cancer cells, making it a targeted therapy. The company's eHSCs are utilized in various treatment modalities such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates, providing solutions for blood cancers. Vor Biopharma, Inc. also has a collaboration agreement with Akron BioProducts for the development and manufacture of cGMP nucleases.
